Eli Lilly and Company announced the election of Carolyn R. Bertozzi, Ph.D., to its board of directors, with her term set to begin on December 8, 2025. The announcement was made in a press release and included in a recent SEC filing. Dr. Bertozzi is a distinguished professor at Stanford University and an Investigator at the Howard Hughes Medical Institute. Upon joining the board, Dr. Bertozzi will serve on the Science and Technology Committee and the Ethics and Compliance Committee. Eli Lilly's board has determined that she meets the independence standards of the New York Stock Exchange. There was no market reaction analysis available for this specific announcement.